key: cord-1019997-j40xvxz1 authors: Jangra, Sonia; Ye, Chengjin; Rathnasinghe, Raveen; Stadlbauer, Daniel; Krammer, Florian; Simon, Viviana; Martinez-Sobrido, Luis; García-Sastre, Adolfo; Schotsaert, Michael title: SARS-CoV-2 spike E484K mutation reduces antibody neutralisation date: 2021-04-07 journal: Lancet Microbe DOI: 10.1016/s2666-5247(21)00068-9 sha: 35303cdba5b11cfad389f86f4aa624dec805ec3e doc_id: 1019997 cord_uid: j40xvxz1 nan Methods section: 50% tissue culture infective dose (TCID50) calculation and in vitro microneutralization assay: To estimate the neutralizing efficiency of human sera, in vitro microneutralization assays were performed. Human sera were inactivated at 56°C for 30 min. Serum samples were serially diluted 3-fold starting from 1:30 dilution in Vero-E6-infection medium (DMEM+ 2% FBS+ 1% non-essential amino acids). The samples were incubated with 450 tissue culture infective dose 50 (TCID50) of either USA-WA1/2020 or rSARS-CoV-2 E484K for 1 hour in an incubator at 37°C, 5% CO2 followed by incubation with pre-seeded Vero-E6 at 37°C for 48 hours. The plates were fixed in 4% formaldehyde at 4°C overnight. For TCID50 calculation, the virus stock was serially diluted 10-fold starting with 1:10 dilution and incubated on Vero-E6 cells for 48 hours followed by fixation in 4% Formaldehyde. The cells were washed with 1xPBS and permeabilized with 0.1% Triton X-100 in 1XPBS. The cells were washed again and blocked in 5% non-fat milk in 1xPBS+ 0.1% Tween-20 for 1 hour at room temperature. After blocking, the cells were incubated with anti-SARS-CoV-2 NP and anti-spike monoclonal antibodies, mixed in 1:1 ratio, for 1.5 hours at room temperature. The cells were washed in 1xPBS and incubated with 1:5000 diluted HRP-conjugated anti-mouse IgG secondary antibody for 1 hour at RT followed by a brief PBS wash. Finally, 100μl tetramethyl benzidine (TMB) substrate was added and incubated at RT until blue color appeared, and the reaction was terminated with 50μl 1M H2SO4. Absorbance was recorded at 450nm and 650nm and percentage reduction in infection was calculated as compared to negative control. We performed all experiments in a blinded manner. The study protocols for the collection of clinical specimens from individuals with and without SARS-CoV-2 infection by the Personalized Virology Initiative were reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-16-00791; IRB-20-03374). All participants provided informed consent prior to collection of specimen and clinical information. All specimens were coded prior to processing. Virus stocks were rescued and grown on Vero E6 cells (multiplicity of infection: 0.05) in infection medium (DMEM+ 2% FBS+ 1% non-essential amino acids) for 3 days. The E484K mutant rSARS-CoV-2 was generated using previously described reverse genetics based on the use of a bacterial artificial chromosome (BAC). 1-3 Viral RNA was extracted from 1ml virus supernatant with TRIzol reagent (ThermoFisher Scientific) according to the manufacturer's instruction. For Sanger sequencing, RT-PCR amplification of the viral genome spanning nucleotides 22853 to 24027 was performed using SuperScript II reverse transcriptase (ThermoFisher Scientific) and the Expand high-fidelity PCR system (Sigma-Aldrich). The 1,175 bp amplified RT-PCR products were subjected to Sanger sequencing (ACGT). The primers used for RT-PCR are available upon request. For deep sequencing of the entire viral genome, we generated libraries using a KAPA RNA HyperPrep kit with a 45-min adapter ligation incubation, including 6 cycles of PCR with 100 ng of viral RNA and a 7 mM adapter concentration. Samples were sequenced on an Illumina HiSeq X machine. The sequencing data were assembled and aligned a SARS-CoV-2 reference genome (GenBank accession no. MN985325) by Integrative Genomic Viewer (IGV 2.9.0). Generation and Characterization of recombinant SARS-CoV-2 expressing reporter genes Generation of Recombinant SARS-CoV-2 Using a Bacterial Artificial Chromosome Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome